Results of Postal Ballot (Clause 35A)
Glenmark Pharmaceuticals Ltd has informed BSE that the members of the Company have passed the resolution by way of Postal Ballot, under Clause 35A.26-11-2014
26-11-2014
Disclosure of Voting results of Court Convened Meeting (Clause 35A)
Glenmark Pharmaceuticals Ltd has informed BSE regarding the details of Voting results at the Court Convened Meeting of Equity Shareholders of the Company held on November 19, 2014, under Clause 35A.21-11-2014
Glenmark Generics receives final ANDA approval for Omeprazole DR Capsules
Glenmark Pharmaceuticals Ltd has informed BSE regarding a Press Release dated November 05, 2014 titled "Glenmark Generics receives final ANDA approval for Omeprazole DR Capsules".05-11-2014
Enrollment Begins of First Patient in Phase II Vatelizumab Trial in Relapsing Remitting Multiple Sclerosis
Glenmark Pharmaceuticals Ltd has informed BSE regarding a Press Release dated November 04, 2014, titled "Enrollment Begins of First Patient in Phase II Vatelizumab Trial in Relapsing Remitting Multiple Sclerosis".04-11-2014
Outcome of Board Meeting
Glenmark Pharmaceuticals Ltd has informed BSE that the Board of Directors of the Company at its meeting held on October 30, 2014, inter alia, considered and approved the following matters subject to the consent of members to be taken through Postal Ballot as per the provisions of the Companies Act, 2013 and Rules thereof:a. Raising of funds for an amount not exceeding USD 300 Mn. through issuance of securities including Equity Shares or equity...30-10-2014
Announces Q2 results, Results Press Release & Limited Review Report for the Quarter ended September 30, 2014
Glenmark Pharmaceuticals Ltd has announced the following results for the quarter ended September 30, 2014:The Unaudited Standalone results for the Quarter ended September 30, 2014The Company has posted a net profit of Rs. 1164.27 million for the quarter ended September 30, 2014 as compared to Rs. 1059.48 million for the quarter ended September 30, 2013. Total Income has increased from Rs. 6060.26 million for the quarter ended September...30-10-2014
Court Convened Meeting and Notice of postal ballot
Glenmark Pharmaceuticals Ltd has submitted to BSE a copy of notices pertaining to obtaining approval of the shareholders to the Scheme of Amalgamation of Glenmark Generics Ltd and Glenmark Access Ltd with the Company:1. Notice for Postal Ballot/e-voting.2. Notice for the Court Convened Meeting of the shareholders of Glenmark Pharmaceuticals Limited.22-10-2014
Q2 results on Oct 30, 2014
Glenmark Pharmaceuticals Ltd has informed BSE that a meeting of the Board of Directors of the Company will be held on October 30, 2014, to consider and approve the Company's Unaudited Financial Statements for the Second Quarter/Half year ended September 30, 2014 (Q2).Further, as per the "Code of Conduct for Prevention of Insider Trading" of the Company, the trading window shall remain closed for Directors and other designated employees of...17-10-2014
Outcome of Committee Meeting
Glenmark Pharmaceuticals Ltd has informed BSE that the Operations Committee of the Board of Directors of the Company, at its Meeting held on October 10, 2014 allotted 11,500 shares to the employees of the Company on exercise of options granted to them pursuant to ESOS 2003.13-10-2014
Shareholding Pattern For September 30, 2014
Glenmark Pharmaceuticals Ltd has informed BSE about the Shareholding Pattern as on September 30, 2014.08-10-2014